Clinical-stage biopharma Immunomedics (Nasdaq:IMMU) is a heavyweight player soaring in the worldwide antibody-drug conjugate (ADC) market. In other words, IMMU specializes in cancer therapies; and it’s been a standout year for investors.

Notably, IMMU’s lead investigational ADC is IMMU-132 (sacituzumab govitecan), designed for heavily pre-treated patients with ER+ and HER2-metastatic breast cancer.

It’s been a year of rapid-fire growth for IMMU. The stock has rocketed 51% in 2018 alone; and 103% in year-over-year growth. Momentum doesn’t seem to be trailing for the mid-cap company either. After all, shares were rising almost 6% on Monday, and continue to jump another 2% Tuesday morning.

What’s got bulls all riled up on Immunomedics? Ever since the drug maker posted its fourth fiscal print for 2018, shares have surged close to 9%.

Here, we turn to TipRanks’ data to get a better sense of the bigger picture- and determine if the indicators are pointing to a compelling biotech investment prospect.

A Closer Look at the Bullish Picture 

First, we can see that based on over 58,000 best-performing investor portfolios analyzed by TipRanks, sentiment here is bullish. In the last 30 days, top investors have boosted portfolios by 0.4%.

Next, we can see blogger sentiment is upbeat on Immunomedics’ market opportunity. Compared to other names in the Healthcare sector, bloggers are more positive. In fact, one blogger picked IMMU as one of the top 10 best stocks of 2017.

Looking at the last three months, we can see that insiders have dialed up IMMU shares- a monster upturn worth over $18 million.

What is ‘smart money’ doing? Five-star hedge fund manager Peter Kolchinsky of RA Capital Management (Profile & Recommendations) initiated a new stake in IMMU in the latest quarter worth $73.85 million. The biotech player takes a roughly 5% of Kolchinsky’s portfolio. Notably, Kolchinsky is ranked top #14 among over 200 hedge funds we track on TipRanks.